{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:01:26Z","timestamp":1791331286525,"version":"4.3.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K16245"],"award-info":[{"award-number":["21K16245"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018289","name":"The Shinnihon Foundation of Advanced Medical Treatment Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017682","name":"Japanese Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017682","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018507","name":"Japan Medical Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018507","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.bneo.2024.100001","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T01:52:54Z","timestamp":1707443574000},"page":"100001","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["KIR3DL1-HLA-Bw status in CML is associated with achievement of TFR: the POKSTIC trial, a multicenter observational study"],"prefix":"10.1016","volume":"1","author":[{"given":"Hiroshi","family":"Ureshino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2028-0209","authenticated-orcid":false,"given":"Shin","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1216-4470","authenticated-orcid":false,"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1836-0464","authenticated-orcid":false,"given":"Shugo","family":"Kowata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7353-3495","authenticated-orcid":false,"given":"Kazunori","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asao","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0754-9568","authenticated-orcid":false,"given":"Motohiro","family":"Shindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoharu","family":"Takeoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuharu","family":"Kamachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kidoguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2085-6151","authenticated-orcid":false,"given":"Takero","family":"Shindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Iyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Inamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5600-5762","authenticated-orcid":false,"given":"Tsutomu","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9377-443X","authenticated-orcid":false,"given":"Eri","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ohkawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ikezoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.bneo.2024.100001_bib1","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.bneo.2024.100001_bib2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2024.100001_bib3","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bneo.2024.100001_bib4","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2024.100001_bib5","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10147-018-1368-2","article-title":"Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)","volume":"24","author":"Fujisawa","year":"2019","journal-title":"Int J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bneo.2024.100001_bib6","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.bneo.2024.100001_bib7","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S2352-3026(19)30235-2","article-title":"Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial","volume":"7","author":"Kimura","year":"2020","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.bneo.2024.100001_bib8","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.bneo.2024.100001_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.106273","article-title":"Role of cancer immunology in chronic myelogenous leukemia","volume":"88","author":"Ureshino","year":"2020","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.bneo.2024.100001_bib10","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2024.100001_bib11","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2024.100001_bib12","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","article-title":"Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study","volume":"102","author":"Rea","year":"2017","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.bneo.2024.100001_bib13","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"issue":"6013","key":"10.1016\/j.bneo.2024.100001_bib14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"issue":"20","key":"10.1016\/j.bneo.2024.100001_bib15","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1200\/JCO.2016.70.7059","article-title":"KIR3DL1\/ HLA-B subtypes govern acute myelogenous leukemia relapse after hematopoietic cell transplantation","volume":"35","author":"Boudreau","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.bneo.2024.100001_bib16","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1200\/JCO.2015.64.9558","article-title":"KIR3DL1 allelic polymorphism and HLA-B epitopes modulate response to Anti-GD2 monoclonal antibody in patients with neuroblastoma","volume":"34","author":"Forlenza","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.bneo.2024.100001_bib17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1158\/2326-6066.CIR-17-0462","article-title":"Allelic polymorphisms of KIR s and HLA s predict favorable responses to tyrosine kinase inhibitors in CML","volume":"6","author":"Ureshino","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.bneo.2024.100001_bib18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/1535-7163.MCT-20-0336","article-title":"HLA polymorphisms are associated with treatment-free remission following discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"20","author":"Ureshino","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.bneo.2024.100001_bib19","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/ng2035","article-title":"Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1","volume":"39","author":"Martin","year":"2007","journal-title":"Nat Genet"},{"issue":"19","key":"10.1016\/j.bneo.2024.100001_bib20","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1182\/bloodadvances.2020002086","article-title":"HLA-A alleles influencing NK cell function impact AML relapse following allogeneic hematopoietic cell transplantation","volume":"4","author":"van der Ploeg","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.bneo.2024.100001_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.xgen.2022.100101","article-title":"Decoding the diversity of killer immunoglobulin-like receptors by deep sequencing and a high-resolution imputation method","volume":"2","author":"Sakaue","year":"2022","journal-title":"Cell Genomics"},{"issue":"1","key":"10.1016\/j.bneo.2024.100001_bib22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/tan.13881","article-title":"Implications of HLA diversity among regions for bone marrow donor searches in Japan","volume":"96","author":"Hashimoto","year":"2020","journal-title":"HLA"},{"issue":"6","key":"10.1016\/j.bneo.2024.100001_bib23","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s10147-011-0328-x","article-title":"Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan","volume":"17","author":"Yoshida","year":"2012","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bneo.2024.100001_bib24","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bneo.2024.100001_bib25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.20051884","article-title":"Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function","volume":"203","author":"Yawata","year":"2006","journal-title":"J\u00a0Exp Med"},{"issue":"8","key":"10.1016\/j.bneo.2024.100001_bib26","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.4049\/jimmunol.1502469","article-title":"KIR3DL1 and HLA-B density and binding calibrate NK education and response to HIV","volume":"196","author":"Boudreau","year":"2016","journal-title":"J\u00a0Immunol"},{"issue":"5","key":"10.1016\/j.bneo.2024.100001_bib27","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1084\/jem.20152023","article-title":"Killer cell immunoglobulin-like receptor 3DL1 polymorphism defines distinct hierarchies of HLA class I recognition","volume":"213","author":"Saunders","year":"2016","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"10.1016\/j.bneo.2024.100001_bib28","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4049\/jimmunol.2001109","article-title":"The role of the HLA class I \u03b12 helix in determining ligand hierarchy for the killer cell Ig-like receptor 3DL1","volume":"206","author":"Saunders","year":"2021","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.bneo.2024.100001_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2017.00675","article-title":"HLA-Bw4-I-80 isoform differentially influences clinical outcome as compared to HLA-Bw4-T-80 and HLA-A-Bw4 isoforms in rituximab or dinutuximab-based cancer immunotherapy","volume":"8","author":"Erbe","year":"2017","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.bneo.2024.100001_bib30","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1056\/NEJMoa1200503","article-title":"HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1","volume":"367","author":"Venstrom","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.bneo.2024.100001_bib31","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood-2014-05-572065","article-title":"KIR ligand C2 is associated with increased susceptibility to childhood ALL and confers an elevated risk for late relapse","volume":"124","author":"Babor","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2024.100001_bib32","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.bbmt.2006.04.008","article-title":"KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy","volume":"12","author":"Hsu","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.bneo.2024.100001_bib33","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/ijc.25233","article-title":"The BCR\/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity","volume":"127","author":"Salih","year":"2010","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.bneo.2024.100001_bib34","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2011.056853","article-title":"Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia","volume":"97","author":"Takahashi","year":"2012","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.bneo.2024.100001_bib35","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00277-015-2326-y","article-title":"The interferon-alpha revival in CML","volume":"94","author":"Talpaz","year":"2015","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.bneo.2024.100001_bib36","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ajh.26550","article-title":"Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors","volume":"97","author":"Haddad","year":"2022","journal-title":"Am J Hematol"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T02:10:32Z","timestamp":1768615832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328024000013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2950328024000013"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100001","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KIR3DL1-HLA-Bw status in CML is associated with achievement of TFR: the POKSTIC trial, a multicenter observational study","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100001"}}